Can an oral PCSK9 inhibitor lower LDL effectively?

Special Edition of the JAMA Editor's Summary featuring JAMA Network articles published at the 2025 AHA Scientific Sessions. Hosted by JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content:

• Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
• Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk
• Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation
• DASH-Patterned Groceries and Effects on Blood Pressure
• Coronary Computed Tomography Angiography in Prediction of First Coronary Events
• Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease
• Physical Activity and Cardiovascular Outcomes in Phenotype-Negative Cardiomyopathy Variant Carriers
• Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy
• Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy
• Clonal Hematopoiesis and Incident Heart Failure
• Chronic Kidney Disease Prevalence and Awareness Among US Adults
• Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer
• Prenatal Care and Perinatal Regionalization for Congenital Heart Defects
• Lifestyle Intervention for Sustained Remission of Metabolic Syndrome